Compared to placebo what was the result of alogliptin on HbA1c level?
From baseline to the end of the study, there was a consistently significant relative reduction in HbA1c in the alogliptin group as compared with placebo in each baseline HbA1c category (Figure 1). The least‐squares mean difference in change from baseline between alogliptin and placebo was most pronounced for patients with HbA1c ≥ 9.0% (75 mmol/mol) at baseline (least‐squares mean difference −0.54% [6 mmol/mol], 95% CI −0.74%, −0.34%; P < .001).